[针对IL-5的生物技术剂的不良反应]
Guillermo Pérez-Dimas1, Citlali Ramírez-Casillas2, Itzel Yoselin Sánchez-Pérez2
1Alergia e Inmunología Clínica, Hospital General de México Dr. Eduardo Liceaga, CDMX, México. pdimasg@gmail.com.
概括
严重喘患者可能会经历诸如本拉利祖马布和梅波利祖马布之类的生物治疗的副作用. 仔细监测对于管理这些先进疗法和确保患者在喘管理中的安全至关重要.
科学领域:
- 肺部病理学 肺部病理学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 严重的喘,特别是带有eosinophilic表型的喘,在治疗控制和恶化管理方面存在挑战.
- 生物技术药物,包括向互白素-5 (IL-5) 或其受体 (IL-5Rα) 的单克隆抗体,适用于患有严重,不受控制的酸性喘的患者.
- 尽管有效,但这些先进疗法具有潜在的不良影响,需要仔细识别和管理.
研究的目的:
- 报告使用本拉利祖马布治疗严重喘并随后转换为梅波利祖马布的病例,突出治疗挑战和不良事件.
- 讨论与严重喘IL-5Rα向治疗相关的安全性和不良影响.
- 强调在喘管理中监测生物制剂常见和不常见的不良影响的重要性.
主要方法:
- 一份病例报告详细介绍了一名24岁的女性,患有持续的不受控制的喘和过敏性鼻炎,接受了皮下免疫疗法和吸入性皮质类固醇/长效β-agonists治疗.
- 开始使用本拉利祖马布30毫克治疗失控喘 (ACT 16分),尽管基于指南的治疗升级到第4步.
- 由于不良反应 (发烧,头痛,肌痛,关节痛) 而停止本拉利祖马布治疗,随后转换为梅波利祖马布,在第三剂后报告了不良反应.
主要成果:
- 患者经历了本拉利祖马布的临床改善,但产生了全身不良反应,导致治疗停止.
- 转换为梅波利祖马布也导致第三剂后的不良反应,表明潜在的类相关或个体敏感性.
- 文献审查表明,虽然单克隆抗体减少了恶化并改善了生活质量,但报告的副作用包括上呼吸道感染,头痛和关节痛.
结论:
- 针对IL-5通路的生物技术药物对于治疗严重的酸性喘至关重要,但与不良影响有关.
- 即使是这些先进疗法的不常见副作用,也需要进行彻底的鉴定和评估,以确定其是否适合继续治疗.
- 必须仔细评估个体患者的反应和潜在的不良事件,以优化严重喘管理策略.
相关概念视频
T Cell Types and Functions
2.2K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.2K
Allergic Drug Reactions
1.3K
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
1.3K
Immunodeficiency Diseases
2.0K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
There are three main causes of immunodeficiency...
2.0K
Tumor Immunotherapy
1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
Cell-mediated Immune Responses
83.5K
Overview
83.5K
Hypersensitivities
7.2K
Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
7.2K
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)

